https://www.selleckchem.com/products/gbd-9.html
This treatment could stimulate the biological processes that maintain homeostasis and bone structure and avoid osteoarticular pathologies. © 2020 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate- or high-risk myelofibrosis who were resistant or intolerant to prior ruxolitinib per investigator assessment. Patients received fedratinib 400 mg/day in 28-day cycles. JAKARTA2 outcomes w
Like
Comment
Share
